EDDING GENOR

Edding Genor opened lower and continued to decline, bottoming at HKD 1.620 in the afternoon session before a slight recovery to close at HKD 1.630, down 4.68% from the previous close of HKD 1.710, with a thin turnover of 608,500 shares and a turnover rate of only 0.03%. The subdued price action is mainly attributed to the company's recent series of share repurchase disclosures (with a maximum buyback price of HKD 1.92), yet market skepticism persists regarding the repurchase scale and the sustainability of earnings improvement. Despite Q4 2025 revenue of HKD 752 million growing 20.5% YoY and net profit of HKD 158 million surging 156.8% YoY (EPS HKD 0.0787), the stock remains 70.89% below its 52-week high of HKD 5.60 and trades below both the MA20 (HKD 1.864) and MA60 (HKD 1.996), indicating limited valuation recovery momentum. However, the stock's PB of 0.76x is near its historical trough.

Edding Genor opened lower and extended losses in the afternoon session, closing at HKD 1.78, down 5.32% on a 5.38% intraday range. The trigger was persistent pressure from the 20-day moving average (HKD 1.868), and a flurry of at least ten share buyback disclosures over the past month—repurchasing at prices up to HKD 1.92 and as low as HKD 1.85—failed to reverse sentiment, with today's close falling below those levels. Despite strong Q4 2025 earnings showing revenue of HKD 752 million (+20.5% YoY) and net profit of HKD 158 million (+156.8% YoY), the stock remains under water. The PB multiple is 0.83x, PE 8.01x, the YTD decline stands at -38.62%, and the price is 68.21% below its 52-week high of HKD 5.6, well below the 60-day MA of HKD 2.04. While the company's recent US$48.4 million Candid stake sale and NMPA nod for the GB268 Phase Ib/II trial could provide future catalysts, the near-term technical picture remains weak.

Edding Genor opened lower and drifted down, briefly hitting an intraday low of HK$1.83 during the morning session before closing at HK$1.90, down 5.9% from the prior close of HK$2.02, with total turnover of 980,500 shares as afternoon session buying near the average price of HK$1.900 provided modest support. The company has realized US$48.4 million from the sale of its Candid stake following the UCB takeover, has been conducting on-market share repurchases, and its trispecific breast cancer antibody GB268 received NMPA approval for a Phase Ib/II trial. However, the stock remains under pressure with a YTD decline of 35.2%, 66.4% below its 52-week high of HK$5.60, and trading below the 60-day MA of HK$2.212, while the price-to-book ratio stands at 0.88x. The afternoon rebound from the session low of HK$1.850 to HK$1.900 suggests some bargain-hunting near the historical low area.

6998.HK closed at HKD 2.000, up 5.82% in a session that rebounded from an intraday low. The stock opened at 1.940, dipped to the previous close of 1.890 at 09:30 BJ, then surged to an intraday high of 2.090 by 10:38 BJ, before fading throughout the afternoon to 2.000. The catalyst was a series of share repurchase disclosures, including four next-day filings and an earlier mandate to buy back up to 10% of shares on-market. However, the afternoon session was marked by declining volume and a pullback to near the session open, with the closing price still well below the MA60 (HKD 2.257) and the stock down 31.03% YTD, 64.29% off its 52-week high, suggesting the buyback-driven rally lacked follow-through conviction.

Edding Genor Group opened lower and continued to decline, closing down 5.08% at HKD 1.870, with an intraday low of HKD 1.870 in the afternoon session, extending its losing streak for a second consecutive day. The decline was primarily driven by persistent market concerns over fundamentals, despite the company's recent share repurchase disclosures. While Q4 2025 net profit surged 156.82% YoY to HKD 158.3 million and revenue grew 20.5% to HKD 751.7 million, with EPS of HKD 0.0787 (up 112.91% YoY), the stock remains below its MA60 (HKD 2.299) and has declined 35.52% YTD, trading at a 66.61% discount to its 52-week high of HKD 5.6. However, the company recently received NMPA approval for a Phase Ib/II trial of its trispecific antibody GB268 for breast cancer, signaling continued pipeline progress.